<DOC>
	<DOCNO>NCT00051493</DOCNO>
	<brief_summary>The purpose study evaluate effect ( good bad ) LY231514 ( ALIMTA ) Carboplatin non-small cell lung cancer .</brief_summary>
	<brief_title>ALIMTA Plus Carboplatin Front-Line Chemotherapy Patients With Locally Advanced Metastatic Non-Small Cell Lung Cancer : A Phase 2 Clinical Trial .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>You diagnosis nonsmall cell lung cancer . You receive prior chemotherapy . You least one measurable lesion . You adequate performance status . You least 18 year age . You previously receive chemotherapy lung cancer . You receive radiation within last 30 day . You active infection serious condition . You brain metastasis . You recently lose significant amount weight .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
</DOC>